RXRX vs. RLAY

In the year-to-date period, RXRX achieves a -3.40% return, which is significantly lower than RLAY's 8.25% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and Relay Therapeutics, Inc. (RLAY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RXRX Sharpe Ratio is -0.42, which is higher than the RLAY Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of RXRX and RLAY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RXRX nor RLAY has paid dividends to shareholders.

The maximum RXRX drawdown since its inception was -88.97%, smaller than the maximum RLAY drawdown of -93.81%. Use the drawdown chart below to compare losses from any high point for RXRX and RLAY. For additional features, visit the drawdowns tool.

Recursion Pharmaceuticals, Inc. (RXRX) and Relay Therapeutics, Inc. (RLAY) have volatilities of 28.74% and 28.75%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Recursion Pharmaceuticals, Inc. and Relay Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.